| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Carolyn E. Taylor is Director at TNXP. Carolyn E. Taylor's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $10K at current prices.
Net of sales, the TNXP filings show accumulation of 1,833 shares.
Carolyn E. Taylor has 8 Form 4 filings on record from July 2021 to June 2026, all as Director at Tonix Pharmaceuticals (TNXP), 2021–2026.
The 8 reported transactions were 6 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $30K and no sales.
The largest open-market purchase was 418 shares of TNXP at an average $36.03 on August 21, 2025, about $15K. Twelve months later TNXP was down 65%.